pharmaceutical investing RYBREVANT FASPRO plus LAZCLUZE® with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 15 September
pharmaceutical investing Johnson & Johnson's RYBREVANT® plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer 13 September
